Investor Alert

New York Markets Open in:


Heart Disease

5:57 a.m. Aug. 30, 2020 - By Quentin Fottrell
An analysis of data from 28,000 patients sheds more light on blood-pressure issues and COVID-19 ‘At the start of the pandemic, there was concern that specific medications for high blood pressure could be linked with worse outcomes for COVID-19 patients’‘At the start of the pandemic, there was concern that specific medications for high blood pressure could be linked with worse outcomes for COVID-19 patients.’
7:25 a.m. June 23, 2020 - By Jaimy Lee
Researchers publish dexamethasone findingsResearchers on Monday published that led to the U.K.'s decision to approve the steroid dexamethasone as a treatment for some severely ill COVID-19 patients. The U.K. preliminary findings from the trial last week. The study is in preprint form and has not been peer-reviewed, which is considered the gold standard in clinical research. However, during the coronavirus pandemic, preprints have become a popular way to more quickly release scientific data about the virus and potential treatments. The U.K.'s randomized study assessed the use of dexamethasone in 2,104 patients. An additional 4,321 patients received the standard of care. About 21.6% of the patients who received the steroid died, compared with 24.6% of the patients who had the standard of care. Of the patients who received the steroid who were on mechanical ventilators, 29.0% died, compared with 40.7% of patients on ventilators receiving the standard of care. And among patients receiving oxygen and dexamethasone, 21.5% died, as compared to 25.0% of patients who received oxygen and the standard of care. The drug did not benefit COVID-19 patients who were not receiving oxygen or ventilation in the study. The mean age of the clinical study's participants was about 66 years old; about two-thirds of patients in the trial were men; and about half of the patients who received dexamethasone had a pre-existing condition, such as diabetes or heart disease. "Dexamethasone provides an effective treatment for the sickest patients with [COVID-19] and, given its low cost, well-understood safety profile, and widespread availability, is one that can be used worldwide," the University of Oxford researchers concluded.
11:58 a.m. April 23, 2020 - By Ciara Linnane
Coronavirus update: Hong Kong study says China’s true case tally is likely four times as high as officially reported numbers Gap has stopped paying rent totaling about $115 million in North America, and Domino’s Pizza beats sales and profit views in latest quarterChina’s constantly shifting methodology for counting the number of cases of the coronavirus that causes COVID-19 has led it to greatly understate the numbers and the true tally may be four times the official figures, according to a new study by researchers in Hong Kong.
Browse topics:

Filter results by


Us (104)

Europe (15)

Eu (12)

Asia Pacific (11)

China (9)

Uk (3)

Link to MarketWatch's Slice.